NAUT - NASDAQ

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%

HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$327.86M

EPS-0.4700

P/E Ratio-5.49

Earnings Date08/04/2026

naut

Net Common Stock Issuance

Last Annual Value

214.00K

3-Year CAGR

-28%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Nautilus Biotechnology, Inc. Competitors Analysis of Net Common Stock Issuance

NAUT · NASDAQ

Company	Net Common Stock Issuance	CAGR 3Y	CAGR 5Y	CAGR 10Y
Nautilus Biotechnology, Inc. NASDAQ:NAUT	214.00K	-16.5%	N/A	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	108.41M	203.8%	-10.5%	N/A
Zura Bio Limited NASDAQ:ZURA	5.20M	-64.5%	-48.3%	N/A
Humacyte, Inc. NASDAQ:HUMA	113.44M	485.2%	N/A	N/A
Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT	13.38M	180.1%	91.8%	N/A
Sagimet Biosciences Inc. NASDAQ:SGMT	275.00K	-85.5%	N/A	N/A
Immuneering Corporation NASDAQ:IMRX	226.58M	100.3%	13.5%	N/A
Agenus Inc. NASDAQ:AGEN	36.22M	-34.3%	-30.2%	37.5%
Cognition Therapeutics, Inc. NASDAQ:CGTX	37.09M	90.9%	-3.5%	N/A
Context Therapeutics Inc. NASDAQ:CNTX	-15.27K	N/A	N/A	N/A
TuHURA Biosciences, Inc. NASDAQ:HURA	21.92M	N/A	31.4%	10.0%

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

HIDDEN

Intrinsic Value

Current Price: $2.58

Related Guides

Blog Categories

Continue your NAUT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.